

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being transmitted via the Office electronic filing system in accordance with § 1.6(a)(4).

Dated: October 3, 2008

Electronic Signature for Amy E. Mandragouras, Esq.: /Amy E. Mandragouras/

Docket No.: SYNI-007RCE2  
(PATENT)

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Patent Application of:  
John Fitzgerald Kokai-Kun *et al.*

Application No.: 10/724,194

Confirmation No.: 1338

Filed: December 1, 2003

Art Unit: 1645

For: WALL TEICHOIC ACID AS A TARGET  
FOR ANTI-STAPHYLOCOCCAL  
THERAPIES AND VACCINES

Examiner: V. A. Portner

MS Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT (SIDS)**

Dear Sir:

In accordance with 37 CFR 1.97, Applicants hereby make of record the following additional documents. A PTO Form SB/08 and a full copy of each of the documents required under 37 CFR 1.98(a)(2) accompany this statement.

Applicants have become aware of the following documents A1 and B1, cited during the prosecution of European Patent Application No. 03796528.2, which corresponds to the above referenced application, and in accordance with 37 CFR 1.97(c) and (e)(1) or (b)(3), hereby submit these documents for the Examiner's consideration. These documents are cited on the enclosed PTO Form SB/08, and a copy of the Office Action and of each document required under 37 CFR 1.98(a)(2) cited thereon are enclosed as well.

Applicants have not submitted a copy of the cited U.S. patent in accordance with 37 CFR 1.98(a)(2)(ii). Applicants submit herewith copies of foreign patents and non-patent references in accordance with 37 CFR 1.98(a)(2).

Please note that Applicants' attorney does not include in this Supplemental Information Disclosure Statement references Aly, "Role of teichoic acid...", US 2002/051793, US 2003/113350 and Weidenmaier, "Role of teichoidic acids...", cited in the corresponding European Office Action. These references were previously submitted in Information Disclosure Statements to the U.S. Patent Office in this case.

This statement is not to be interpreted as a representation that the cited documents are material, that an exhaustive search has been conducted, or that no other relevant information exists. Nor shall the citation of any document herein be construed *per se* as a representation that such document is prior art. Moreover, Applicants understand the Examiner will make an independent evaluation of the cited documents.

This Supplemental Information Disclosure Statement is filed more than three months after the U.S. filing date, and after the mailing date of the first Office Action on the merits, but before the mailing date of a Final Office Action or Notice of Allowance (37 CFR 1.97(c)).

Please charge our Deposit Account No. 12-0080 in the amount of \$180.00 covering the fee set forth in 37 CFR 1.17(p). The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 12-0080, under Order No. SYNI-007RCE2.

Dated: October 3, 2008

AEM/MBC/mch

Respectfully submitted,

Electronic signature: /Amy E. Mandragouras/  
Amy E. Mandragouras, Esq.  
Registration No.: 36,207  
LAHIVE & COCKFIELD, LLP  
One Post Office Square  
Boston, Massachusetts 02109-2127  
(617) 227-7400  
(617) 742-4214 (Fax)  
Attorney/Agent For Applicants